This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Ocera Therapeutics Inc.
Drug Names(s): TZP-102
Description: TZP-102 is an orally available ghrelin agonist. Ghrelin is a peptide hormone known to stimulate both gastrointestinal motility and growth hormone release. TZP-102 was designed to affect gastrointestinal motility, but not growth hormone release, in order to avoid potential endocrine side effects. It is being developed for mild to moderate gastroparesis.
Additional information available to subscribers only: